Backgrounds/Aims
This study aimed to compare the minimally invasive pancreatoduodenectomy with venous vascular resection (MI-PDVR) and open pancreatoduodenectomy with venous vascular resection (O-PDVR) for periampullary cancer.
Methods
Data of 124 patients who underwent PDVR (45 MI-PDVR, 79 O-PDVR) between January 1, 2016, and December 31, 2023, was retrospectively reviewed.
Results
MI-PDVR is significantly better than O-PDVR in terms of perioperative outcomes (median operation time [452.69 minutes vs. 543.91 minutes;
p
= 0.004], estimated blood loss [410.44 mL vs. 747.59 mL;
p
< 0.01], intraoperative transfusion rate [2 cases vs. 18 cases;
p
= 0.01], and hospital stay [18.16 days vs. 23.91 days;
p
= 0.008]). The complications until the discharge day showed no significant difference between the two groups (Clavien–Dindo < 3, 84.4% vs. 82.3%; Clavien–Dindo ≥ 3, 15.6% vs. 17.7%;
p
= 0.809). In terms of long-term oncological outcomes, there was no statistical difference in overall survival (OS, 51.55 months [95% CI: 35.95–67.14] vs. median 49.92 months [95% CI: 40.97–58.87];
p
= 0.340) and disease-free survival (DFS, median 35.06 months [95% CI: 21.47–48.65] vs. median 38.77 months [95% CI: 29.80–47.75];
p
= 0.585), between the two groups. Long-term oncological outcomes for subgroup analysis focusing on pancreatic ductal adenocarcinoma also showed no statistical differences in OS (40.86 months [95% CI: 34.45–47.27] vs. 48.48 months [95% CI: 38.16–58.59];
p
= 0.270) and DFS (24.42 months [95% CI: 17.03–31.85] vs. 34.35 months, [95% CI: 25.44–43.27];
p
= 0.740).
Conclusions
MI-PDVR can provide better perioperative outcomes than O-PDVR, and has similar oncological impact.